KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageDebt RatioDebt to EquityEnterprise ValueEquity AverageEquity RatioInvested Capital

AbCellera Biologics (ABCL) Equity Ratio (2020 - 2025)

Historic Equity Ratio for AbCellera Biologics (ABCL) over the last 6 years, with Q3 2025 value amounting to 0.71.

  • AbCellera Biologics' Equity Ratio fell 815.03% to 0.71 in Q3 2025 from the same period last year, while for Sep 2025 it was 0.71, marking a year-over-year decrease of 815.03%. This contributed to the annual value of 0.78 for FY2024, which is 24.0% up from last year.
  • Latest data reveals that AbCellera Biologics reported Equity Ratio of 0.71 as of Q3 2025, which was down 815.03% from 0.72 recorded in Q2 2025.
  • AbCellera Biologics' 5-year Equity Ratio high stood at 0.85 for Q1 2021, and its period low was 0.71 during Q3 2025.
  • For the 5-year period, AbCellera Biologics' Equity Ratio averaged around 0.78, with its median value being 0.78 (2023).
  • As far as peak fluctuations go, AbCellera Biologics' Equity Ratio crashed by 1058.51% in 2022, and later skyrocketed by 638.75% in 2023.
  • Over the past 5 years, AbCellera Biologics' Equity Ratio (Quarter) stood at 0.78 in 2021, then increased by 2.89% to 0.8 in 2022, then decreased by 3.25% to 0.77 in 2023, then rose by 0.24% to 0.78 in 2024, then dropped by 8.41% to 0.71 in 2025.
  • Its Equity Ratio was 0.71 in Q3 2025, compared to 0.72 in Q2 2025 and 0.76 in Q1 2025.